written by reader The Code of Life

By pacraig, July 27, 2017

Anyone have an idea of Michael Robinson’s latest pitch on: THE CODE OF LIFE ?
Seems a tiny gene editing company won their patent lawsuits and is set to change the face of medicine. Big announcement said to be coming
on August 8th.

Any Ideas Regulars ???
Request by: Peter Craig

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

11 Comments
Inline Feedbacks
View all comments
Marylander
Member
July 27, 2017 9:35 pm

Probably EDIT, Editas Medicine, Inc.
-Marylander

nick825
nick825
July 28, 2017 12:01 am

is that right ?is that wrong?what say you all/

SgtJoe
Guest
SgtJoe
August 2, 2017 10:44 pm
Reply to  nick825

I don’t think you are correct. I think I might know what the company is but will remain silent until after the big announcement. I’m buying lots of stock though.

Add a Topic
5971
Randy Peterson
Member
Randy Peterson
July 28, 2017 6:40 am

EDIT is a $600 million company, not the $6 million company advertised by Robinson

Marylander
Member
July 28, 2017 4:32 pm
Reply to  Randy Peterson

1) Mr. Robinson repeatedly referred to a company with $6 M in revenue, but he never described the company’s market cap. He also repeatedly referred to it as a $6 M company in the same contexts in which he had described its $6 M of revenue for the previous year, so he made it clear that his use of term “$6 M company” meant a company with “$6 M in revenues.”
EDIT had $6 M in revenues for the previous four quarters…

2) Mr. Robinson referred to a company which had won an appellate decision involving the USPTO on 2/15/20176 and explained that was crucial for its monetization of its 40 patents and that its stock climbed 30% within a day.
A “non-profit” named the Broad Institute is associated with EDIT, is involved with the same gene repair technology, and won just such a USPTO decision on 2/15/2017, after which the press releases celebrated the decision as good news for EDIT. EDIT’s stock climbed 30% within a day and within weeks climbed 200%, from 15 to 45…

3) Mr. Robinson described a company with 80% insider/institutional ownership.
EDIT has 80% insider/institutional ownership…

4) Mr. Robinson’s description of the appellate decision on 2/15/2017 made it clear that only a company involved in that decision could represent his recommendation, and he was recommending a winner. Only two other companies were involved that day but “lost” in terms of that decision. One has revenues above $20M, and the other $6.5 M in the most recent 3 quarters, being a new company, and only 40% institutional ownership, therefore neither of those other two companies fit any of Mr. Robinson’s stated criteria except for being part of the legal event.
EDIT was part of that 2/15/2017 event and was a beneficiary…

5) The price action of EDIT today (an initial pop and eventual rise of +7.8%) suggests that it is the subject of Mr. Robinson’s advertisements…

I therefore still believe that the company Mr. Robinson was recommending was “Probably EDIT, Editas Medicine, Inc.”

– Marylander

Add a Topic
5971
Add a Topic
5971
mich
July 28, 2017 5:28 pm
Reply to  Marylander

You are probably right, but despite the excitement about the technology, all in the know seem to agree that no money will be made with it for many, many years – perhaps decades. I have looked at the three publicly traded stocks. They all trade around the same value. I personally like CRSP the best. They have better patent protection outside the US and the US fight is far from over. These are currently “story” stocks, but they do have some good science behind them. I have not invested in them because there are no likely profits in sight for many years. They will trade on pumps like this one, court decisions, secondary offerings (dropping the stocks’ prices), and other factors not related to earnin